community download

Presentation: Fluzone

information we require

please check before submitting



Unfortunately the document is not available at this current time, however if you leave your details we'll get it to you as soon as we can.

Please fill in all the information requested. It is very important you enter this information correctly so we can contact you with the document.

Privacy statement »

Manage your email preferences »

Remember my details Information

Information
Remember my details
We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

Efficacy study of Fluzone® High-Dose vaccine compared with Fluzone® in Elderly Adults
• Randomized, modified double-blind, active controlled, multi-center trial
Primary Objective:
• Compare clinical efficacy of Fluzone® HD to Fluzone® in elderly adults, with respect to laboratory confirmed influenza, caused by any viral types/subtypes, associated with a protocol-defined Influenza Like Illness (ILI)
Primary Endpoint
• Occurrences of culture- or PCR-confirmed influenza (_14 days postvaccination) caused by any influenza viral types/subtypes, in association with a protocol-defined ILI.
Importance of FIM12
• FIM12 is the clinical study to prove effectiveness by performing surveillance for respiratory illness and testing for influenza
• A better influenza vaccine for the elderly would:
o Prevent more cases of influenza
o Prevent more cases of influenza complications, including hospitalizations & deaths
• If High Dose is superior, there is potential impact on public health


Why not download the full presentation and discover more about quality and collaboration in a large scale clinical trial for Influenza
• Coordinating several trial sites, and maintaining productivity, communication and mutual communication across the board
• Meeting the challenges of conducting a large scale clinical trial, and what solutions can be offered
• Different perspectives throughout the trial phases – how best to forge an effective relationship between all parties involved in the vaccine clinical trial process.
Janet Christoff, Clinical Study Manager, sanofi Pasteur- World Vaccine Congress WASHINGTON 2012